J. Ochs

发表

Assessment of quality of life among pediatric patients with cancer

R. Mulhern, D. Copeland, F. D. Armstrong, 1989 .

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

R. Govindan, R. Herbst, K. Kelly, 2006, Lung cancer.

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.

M. Kris, D. Cella, R. Herbst, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP).

K. Warner, J. Grous, J. Ochs, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials

G. Giaccone, M. Kris, D. Haber, 2005 .

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

Roy S Herbst, W. Hong, J. Baselga, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

A. Harris, J. Baselga, R. Herbst, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

efit with gefitinib, as well as to search for additional clinical and histologic characteristics.

D. Forman, M. Kris, J. Parsonnet, 2017 .

Phase I study of topotecan for pediatric patients with malignant solid tumors.

W. Furman, C. Pratt, J. Kuttesch, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study.

J. Langston, R. Sanford, A. Gajjar, 1998, Medical and pediatric oncology.

Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy

F. Behm, S. Raimondi, W. Evans, 1991, The Lancet.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Patricia L. Harris, G. Giaccone, M. Kris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Roy S Herbst, Vincent Miller, Rafael Rosell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

G. Giaccone, G. Scagliotti, R. Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

R. McLendon, A. Friedman, D. Bigner, 2006, Clinical Cancer Research.

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.

J. Ochs, 2004, International journal of radiation oncology, biology, physics.

Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital.

M. Hudson, C. Pratt, A. Walter, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS

W. Bowman, M. Abromowitch, J. Simone, 1984, The Lancet.

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

G. Giaccone, R. Herbst, M. Janas, 2009, Journal of Cancer Research and Clinical Oncology.

Quality‐of‐Life Assessment in Cancer Patients

R. Mulhern, L. Kun, J. Ochs, 1988, American journal of clinical oncology.

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

M. Kris, D. Carbone, V. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IQ SCORES AND CRANIAL IRRADIATION

J. Ochs, Richard Berg, MauraL. Campbell, 1982, The Lancet.

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

Diane D. Liu, J. Lee, R. Herbst, 2003, Lung cancer.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.